このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性骨化性線維異形成症(FOP)の参加者におけるパロバロテンの長期安全性と有効性を文書化し、さらに説明する研究 (FOPal)

2026年10月20日 更新者:Ipsen

進行性骨化性線維異形成症(FOP)患者におけるパロバロテンの長期安全性と有効性をさらに詳しく説明するための国際観察レジストリ研究

The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).

FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).

HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).

This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.

The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.

This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.

In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.

調査の概要

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • San Francisco、California、アメリカ、94103
        • 募集
        • The Regents of the University of California
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
      • Edmonton、カナダ
        • 募集
        • Edmonton Clinic Health Academy (ECHA)- University of Alberta
      • Oakville、カナダ
        • 積極的、募集していない
        • Bone Research and Education Centre
      • Toronto、カナダ
        • 募集
        • University Health Network (UHN) - Toronto General

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

8年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

説明

Inclusion Criteria :

  • Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
  • Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.

Exclusion Criteria :

  • Currently participating in a palovarotene clinical trial;
  • Currently participating in any interventional clinical trial for FOP;
  • Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Exposed Cohort

Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information)

Unexposed Cohort

Participants untreated with palovarotene

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
時間枠:From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC).

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
時間枠:From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
時間枠:From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
時間枠:From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.

二次結果の測定

結果測定
メジャーの説明
時間枠
再燃の数
時間枠:ベースラインに含める 12 か月前から 11 年前まで。
ベースラインに含める 12 か月前から 11 年前まで。
参加者ごとに影響を受ける場所の数
時間枠:ベースラインから、毎年11年まで。
ベースラインから、毎年11年まで。
影響を受けた場所の推移(場所が影響を受けた回数)(場所ごと)
時間枠:ベースラインから、毎年11年まで。
ベースラインから、毎年11年まで。
慢性治療のためにパロバロテンに曝露されたFOPと非曝露のFOPを持つ参加者のパロバロテンの年間平均用量
時間枠:ベースラインから6か月ごとに11年まで。
ベースラインから6か月ごとに11年まで。
FOPが露出し、フレアアップ治療のためにパロバロチンに暴露された参加者のためのパロバロチンの平均用量/サイクル
時間枠:ベースラインから6か月ごとに11年まで。
ベースラインから6か月ごとに11年まで。
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
時間枠:From Baseline and every six months up to eleven years.

The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved).

From Baseline and every six months up to eleven years.
Change from Baseline in use of assistive devices
時間枠:From Baseline and every six months up to eleven years.

Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living.

From Baseline and every six months up to eleven years.
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
時間枠:From Baseline and every six months up to eleven years.

Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
時間枠:From Baseline and every six months up to eleven years.

The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
時間枠:From Baseline and every six months up to eleven years.

The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
時間枠:From Baseline and every six months up to eleven years.

The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
時間枠:From Baseline and every six months up to eleven years.

The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test.

From Baseline and every six months up to eleven years.
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
時間枠:From Baseline and every six months up to eleven years.

PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:

  • Global physical health scores will be calculated as the sum of scores from Questions 3, 6, 7 and 8 and will range from 4 (worse health) to 20 (better health);
  • Global mental health scores will be calculated as the sum of scores from Questions 2, 4, 5 and 10 and will range from 4 (worse health) to 20 (better health).
From Baseline and every six months up to eleven years.
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
時間枠:From Baseline and every six months up to eleven years.

PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health).

If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing.

From Baseline and every six months up to eleven years.
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
時間枠:From Baseline and every six months up to eleven years.

The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit.

From Baseline and every six months up to eleven years.
Number of flare-up outcomes
時間枠:From Baseline and every six months up to eleven years.

Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported.

From Baseline and every six months up to eleven years.
Flare-up Duration
時間枠:From Baseline and every six months up to eleven years.

Flare-up duration will be assessed by body location and overall, at each visit.

From Baseline and every six months up to eleven years.
Movement mobility change
時間枠:From Baseline and annually up to eleven years.

Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement)

From Baseline and annually up to eleven years.
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
時間枠:From Baseline and every six months up to eleven years.

The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected.

From Baseline and every six months up to eleven years.
Percentage of participants with any fractures overall
時間枠:From baseline up to 30 days after the last palovarotene dose.

Assessed by radiological imaging and clinical examination.

From baseline up to 30 days after the last palovarotene dose.
Change from Baseline in annualized number of fractures by body location and overall
時間枠:From baseline up to 30 days after the last palovarotene dose.

Assessed by radiological imaging and clinical examination.

From baseline up to 30 days after the last palovarotene dose.
Incidence of pregnancy
時間枠:From Baseline and every month up to 30 days after the last palovarotene dose.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified

From Baseline and every month up to 30 days after the last palovarotene dose.
Description of pregnancy characteristics and outcomes
時間枠:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of pregnancy related Adverse Events (AEs)
時間枠:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of birth and developmental outcomes through the first year after birth
時間枠:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of birth and developmental outcomes through the first year after birth
時間枠:From Baseline and every six months up to eleven years.

Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Change from Baseline in height z-score
時間枠:From Baseline and every six months up to eleven years.

Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Mean difference between chronological age and bone age
時間枠:From Baseline and every six months up to eleven years.

Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Frequency of premature physeal closure (PPC) overall
時間枠:From baseline up to 30 days after the last palovarotene dose

Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From baseline up to 30 days after the last palovarotene dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Ipsen Medical, Director、Ipsen

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月5日

一次修了 (推定)

2035年12月5日

研究の完了 (推定)

2035年12月5日

試験登録日

最初に提出

2023年10月6日

QC基準を満たした最初の提出物

2023年10月13日

最初の投稿 (実際)

2023年10月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月23日

QC基準を満たした最後の更新が送信されました

2026年10月20日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CLIN-60120-453

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD 共有時間枠

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD 共有アクセス基準

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する